Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16048940 | 0.93 | PAOX (0.50) | PAOXSIGMAR1HIF1ATSHRALDH1A1 | |
| SCHEMBL7289625 | 0.86 | TSHR (0.56) | SIGMAR1HIF1ATSHRALDH1A1 | |
| SCHEMBL2561862 | 0.86 | SIGMAR1 (0.46) | PAOXSIGMAR1TSHRALDH1A1CSNK2A2 | |
| SCHEMBL3955905 | 0.84 | TSHR (0.48) | SIGMAR1HIF1ATSHRALDH1A1 | |
| SCHEMBL3947828 | 0.84 | TSHR (0.42) | HIF1ATSHRALDH1A1 | |
| SCHEMBL2592744 | 0.83 | TSHR (0.54) | TSHR | |
| SCHEMBL984275 | 0.81 | HRH3 (0.46) | PAOXHIF1ATSHR | |
| SCHEMBL986238 | 0.81 | HRH3 (0.46) | PAOXHIF1ATSHR | |
| SCHEMBL678406 | 0.81 | HRH3 (0.52) | HIF1ATSHRALDH1A1MAPT | |
| SCHEMBL3951701 | 0.80 | HIF1A (0.38) | PAOXHIF1ATSHRALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968145-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | Mallinckrodt LLC (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014160392-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | MALLINCKRODT LLC (US) | 2014-10-02 | — | — | WO | claimed |
| US-20140271822-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | MALLINCKRODT LLC (US) | 2014-09-18 | — | — | US | claimed |
| CN-113214201-B | Napapucasin derivatives and pharmaceutical application thereof | 毕庶壮 | 2023-08-15 | — | — | CN | disclosed |
| WO-2022251191-A1 | ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-12-01 | — | — | WO | disclosed |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-08-09 | — | — | US | disclosed |
| US-9968554-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-05-15 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
| US-20160250177-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS AND USES THEREOF | MALLINCKRODT US POOL LLC | 2016-09-01 | — | — | US | disclosed |
| EP-2968145-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | Mallinckrodt LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20140356417-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-12-04 | — | — | US | disclosed |
| US-20130236534-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-12 | — | — | US | disclosed |
| US-20130230583-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-05 | — | — | US | disclosed |
| US-20130230582-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-05 | — | — | US | disclosed |
| US-8324410-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-12-04 | — | — | US | disclosed |
| US-20120237591-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-09-20 | — | — | US | disclosed |
| US-20110165225-A1 | Modified Drugs for Use in Liposomal Nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-07-07 | — | — | US | disclosed |
| WO-2009024825-A1 | 2-PYRAZINYLBENZIMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| US-7432378-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-20050070550-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070550-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | PAOX 3295/4885SIGMAR1 835/4885HIF1A 1056/4885 |
| US-20130230582-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | PAOX 2515/4885SIGMAR1 613/4885HIF1A 3213/4885 |
| US-20140271822-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | SGMS2, PHOSPHO1, SGMS1 | PAOX 2277/4885SIGMAR1 3278/4885HIF1A 2910/4885 |
| US-20160250177-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS AND USES THEREOF | LPAR5, LPCAT3, DHCR7 | PAOX 1215/4885SIGMAR1 2721/4885HIF1A 2286/4885 |
| US-20110165225-A1 | Modified Drugs for Use in Liposomal Nanoparticles | ABCB11, SLC47A1, ABCB1 | PAOX 2984/4885SIGMAR1 907/4885HIF1A 3806/4885 |
| US-20120237591-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | PAOX 2515/4885SIGMAR1 613/4885HIF1A 3213/4885 |
| US-20130236534-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | PAOX 2515/4885SIGMAR1 613/4885HIF1A 3213/4885 |
| US-20130230583-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | PAOX 2515/4885SIGMAR1 613/4885HIF1A 3213/4885 |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | PAOX 2984/4885SIGMAR1 907/4885HIF1A 3806/4885 |
| US-20140356417-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | PAOX 2984/4885SIGMAR1 907/4885HIF1A 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.